马上注册，阅读更多内容，享用更多功能！
您需要 登录 才可以下载或查看，没有账号？立即注册 
×
Zipalertinib Plus Chemotherapy for 1st Line NSCLC with EGFR Exon 20 Insertions: Results From the Phase 3 Trial (REZILIENT 3)
D.S. Tan1, P. Danchaivijitr2, Y. Shinno3, C. Ho4,5, J. Zugazagoitia6, T. Inoue7, G-W. Lee8, A.J. de Langen9, A. Sezer10, A. Pender11, C. Dooms12, F. Cappuzzo13, Y. Fujiwara14, Y. Runglodvatana15, A.C. Gelatti16,17,18, S. Novello19, K. Stencel20,21, N. Reguart22, J. Alatorre-Alexander23, G.G-Y. Lai24, N. Girard25, C. Schulz26, Y. Elamin27, M. Nishio28, H. Yu29, B. Besse30, Y. He31, R. Sopariwala31, M. Liu31, V. Wacheck31, F. Benedetti31, J. Heymach27
|
